Search results for "Colore"

showing 10 items of 1250 documents

Anti-proliferative and pro-apoptotic activity of whole extract and isolated indicaxanthin from Opuntia ficus-indica associated with re-activation of …

2014

Phytochemicals may exert chemo-preventive effects on cells of the gastro-intestinal tract by modulating epigenome-regulated gene expression. The effect of the aqueous extract from the edible fruit of Opuntia ficus-indica (OFI extract), and of its betalain pigment indicaxanthin (Ind), on proliferation of human colon cancer Caco-2 cells has been investigated. Whole extract and Ind caused a dose-dependent apoptosis of proliferating cells at nutritionally relevant amounts, with IC50 400 ± 25 mg fresh pulp equivalents/mL, and 115 ± 15 μM (n = 9), respectively, without toxicity for post-confluent differentiated cells. Ind accounted for ∼80% of the effect of the whole extract. Ind did not cause ox…

PyridinesPyridineCellular differentiationBiophysicsIndicaxanthin; Colorectal carcinoma; In vitro; Epigenetic control; Cell cycleIndicaxanthinAntineoplastic AgentsApoptosisCell cycleBiologyBiochemistryPlant ExtractEpigenetic controlAntineoplastic Agentchemistry.chemical_compoundIn vitroSettore BIO/10 - BiochimicaGene expressionHumansMolecular BiologyCyclin-Dependent Kinase Inhibitor p16Cell ProliferationCaco-2 CellCell growthPlant ExtractsApoptosiOpuntiaCell BiologyCell cycleMolecular biologyIn vitroBetaxanthinsColorectal carcinomaSettore BIO/18 - GeneticaBiophysicBiochemistrychemistryCaco-2ApoptosisBetaxanthinCaco-2 CellsIndicaxanthinHumanBiochemical and biophysical research communications
researchProduct

Estimation and prognosis value of elderly colorectal cancer patients' quality of life. : A population-based study

2014

Colorectal cancer is one of the most common malignancies in France and predominantly affects older patients. Few studies evaluating baseline quality of life of those patients, its short term evolution and its prognosis value on patients' survival have been performed in the context of a population-based study. This work is based on a prospective longitudinal cohort study performed by the Burgundy Digestive Cancer Registry. All patients aged 65 and over, diagnosed with a new colorectal cancer and registered by the Registry between 2003 and 2005 were eligible. Among the 401 eligible patients, 246 fulfilled at least one questionnaire. Non-respondents were older and diagnosed with a more advance…

Quality of lifeSurvivalQualité de vieColorectal cancerProxyEtude populationnelleCancer colorectalOlder patientSurvie[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyEtude prospectiveProspective study[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyPatient âgéPopulation-based study
researchProduct

Novel Cancer Chemotherapy Hits by Molecular Topology: Dual Akt and Beta-Catenin Inhibitors

2015

Background and purposeColorectal and prostate cancers are two of the most common types and cause of a high rate of deaths worldwide. Therefore, any strategy to stop or at least slacken the development and progression of malignant cells is an important therapeutic choice. The aim of the present work is the identification of novel cancer chemotherapy agents. Nowadays, many different drug discovery approaches are available, but this paper focuses on Molecular Topology, which has already demonstrated its extraordinary efficacy in this field, particularly in the identification of new hit and lead compounds against cancer. This methodology uses the graph theoretical formalism to numerically chara…

Quantitative structure–activity relationshipCell SurvivalColorectal cancerScienceQuantitative Structure-Activity RelationshipAntineoplastic AgentsComputational biologyBiologyBioinformaticsProstate cancerCell Line TumorNeoplasmsDrug DiscoverymedicineHumansProtein Kinase InhibitorsProtein kinase Bbeta CateninPI3K/AKT/mTOR pathwayBiological ProductsMultidisciplinaryMolecular StructureDrug discoveryTOR Serine-Threonine KinasesQRBiological activitymedicine.diseaseMedicineTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktSignal TransductionResearch ArticlePLOS ONE
researchProduct

Next-to-next-to-leading order N -jettiness soft function for one massive colored particle production at hadron colliders

2017

The $N$-jettiness subtraction has proven to be an efficient method to perform differential QCD next-to-next-to-leading order (NNLO) calculations in the last few years. One important ingredient of this method is the NNLO soft function. We calculate this soft function for one massive colored particle production at hadron colliders. We select the color octet and color triplet cases to present the final results. We also discuss its application in NLO and NNLO differential calculations.

Quantum chromodynamicsPhysicsParticle physicsNuclear and High Energy PhysicsOctet010308 nuclear & particles physicsHadronHigh Energy Physics::PhenomenologyNuclear TheoryOrder (ring theory)FOS: Physical sciences01 natural sciencesHigh Energy Physics - PhenomenologyHigh Energy Physics - Phenomenology (hep-ph)Colored0103 physical sciencesParticleProduction (computer science)High Energy Physics::ExperimentDifferential (infinitesimal)010306 general physicsJournal of High Energy Physics
researchProduct

Probabilities in nonorthogonal basis: Four--quark systems

2009

Four-quark states may exist as colorless meson-meson molecules or compact systems with two-body colored components. We derive an analytical procedure to expand an arbitrary four-quark wave function in terms of nonorthogonal color singlet-singlet vectors. Using this expansion we develop the necessary formalism to evaluate the probability of physical components with an arbitrary four-quark wave function. Its application to characterize bound and unbound four-quark states as meson-meson, molecular, or compact systems is discussed

QuarkPhysicsNuclear and High Energy PhysicsMesonHigh Energy Physics::LatticeNuclear TheoryHigh Energy Physics::PhenomenologyFOS: Physical sciencesFísicaTwo-body problemFormalism (philosophy of mathematics)Color modelHigh Energy Physics - PhenomenologyHigh Energy Physics - Phenomenology (hep-ph)ColoredQuantum mechanicsHigh Energy Physics::ExperimentStatistical physicsWave function
researchProduct

Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study…

2020

BACKGROUND: Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 55·7 months [SD 31·4]) for participants with Lynch syndrome enrolled into a randomised trial of daily aspirin versus placebo. This report completes the planned 10-year follow-up to allow a longer-term assessment of the effect of taking regular aspirin in this high-risk population.METHODS: In the double-blind, randomised CAPP2 trial, 861 patients from 43 international centres worldwide (707 [82%] from Europe, 112 [13%] from Australasia, 38 [4%] from Africa, and four [&l…

RESISTANT STARCHPlacebo-controlled study030204 cardiovascular system & hematology0302 clinical medicineLife Tables030212 general & internal medicine11 Medical and Health Sciencesmedia_commonRISKAspirineducation.field_of_studyAnti-Inflammatory Agents Non-SteroidalLOW-DOSE ASPIRINGeneral MedicineLynch syndrome3. Good healthIntention to Treat AnalysisAnti-Inflammatory Agents Non-Steroidal/adverse effectsmedicine.drugCHEMOPREVENTIONmedicine.medical_specialtyHeterozygote3122 CancersPopulationNEOPLASIAAspirin/adverse effectsPlaceboCAPP2 InvestigatorsMedication Adherence03 medical and health sciencesDouble-Blind MethodInternal medicineGeneral & Internal MedicineColorectal Neoplasms Hereditary Nonpolyposis/geneticsBENEFITSmedicinemedia_common.cataloged_instanceHumansEuropean unioneducationProportional Hazards ModelsIntention-to-treat analysisCancer preventionAspirinbusiness.industryMORTALITY3126 Surgery anesthesiology intensive care radiologymedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisbusinessFollow-Up Studies
researchProduct

Effects of different ras mutations on colorectal cancer cells

2006

Ras colorectal carcinoma HT-29Settore BIO/06 - Anatomia Comparata E Citologia
researchProduct

Re-irradiation With Carbon Ion Radiotherapy for Pelvic Rectal Cancer Recurrences in Patients Previously Irradiated to the Pelvis

2020

Background/Aim: Re-irradiation of locally recurrent rectal cancer poses challenges due to the proximity of critical organs, such as the bowel. This study aimed at evaluating the safety and efficacy of re-irradiation with Carbon Ion Radiotherapy (CIRT) in rectal cancer patients with local recurrence. Patients and Methods: Between 2014 and 2018, 14 patients were treated at the National Center of Oncological Hadrontherapy (CNAO Foundation) with CIRT for locally recurrent rectal cancer. Results: All patients concluded the treatment. No G≥3 acute/late reaction nor pelvic infections were observed. The 1-year and 2-year local control rates were, 78% and 52%, respectively, and relapse occurred clos…

Re-IrradiationAdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerHeavy Ion RadiotherapyKaplan-Meier EstimateGeneral Biochemistry Genetics and Molecular BiologyPelvisRe-Irradiation03 medical and health sciences0302 clinical medicineSettore MED/36 - Diagnostica per Immagini e RadioterapiamedicineHumansIn patientRectal cancer recurrenceCarbon ion radiotherapy; Rectal cancer recurrence; Reirradiation; Adult; Aged; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence Local; Pelvis; Prognosis; Rectal Neoplasms; Tomography X-Ray Computed; Treatment Outcome; Heavy Ion Radiotherapy; Re-IrradiationTomographyPelvisRecurrent Rectal CancerReirradiationAgedPharmacologyddc:617business.industryRectal NeoplasmsMiddle Agedmedicine.diseasePrognosisMagnetic Resonance ImagingX-Ray Computedmedicine.anatomical_structureNeoplasm RecurrenceTreatment OutcomeLocalCarbon ion radiotherapy030220 oncology & carcinogenesisMetastasis free survivalCarbon Ion RadiotherapyFemaleRadiologyNeoplasm Recurrence LocalbusinessTomography X-Ray ComputedPelvic InfectionResearch ArticleFollow-Up Studies
researchProduct

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor

2015

Abstract: Introduction: Receptor tyrosine kinases (RTKs) and their signaling pathways, control normal cellular processes; however, their deregulation play important roles in malignant transformation. In advanced non-small cell lung cancer (NSCLC), the recognition of oncogenic activation of specific RTKs, has led to the development of molecularly targeted agents that only benefit roughly 20% of patients. Entrectinib is a pan-TRK, ROS1 and ALK inhibitor that has shown potent anti-neoplastic activity and tolerability in various neoplastic conditions, particularly NSCLC. Areas covered: This review outlines the pharmacokinetics, pharmacodynamics, mechanism of action, safety, tolerability, pre-cl…

Receptor Protein-Tyrosine KinasesEntrectinibNTRK1NTRK2NTRK3Receptor tyrosine kinaseEntrectinibMalignant transformationAntineoplastic AgentNeoplasmsProtein-Tyrosine KinaseALK; colorectal cancer; Entrectinib; non-small cell lung cancer; NTRK1; NTRK2; NTRK3; precision medicine; ROS1; salivary gland cancer; TrkA; TrkB; TrkC; Animals; Antineoplastic Agents; Benzamides; Humans; Indazoles; Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptor; trkA; Receptor; trkB; Receptor; trkC; Pharmacology; Pharmacology (medical)Anaplastic Lymphoma KinasePharmacology (medical)salivary gland cancerProto-Oncogene ProteinbiologyTrkAPharmacology. TherapyTrkCTrkBGeneral MedicineProtein-Tyrosine KinasesReceptor Protein-Tyrosine KinaseBenzamidesmedicine.symptomROS1ReceptorHumanIndazolesmedicine.drug_classprecision medicineAntineoplastic Agentscolorectal cancerBenzamideProto-Oncogene ProteinsmedicineROS1AnimalsHumansReceptor trkBReceptor trkCReceptor trkAnon-small cell lung cancerPharmacologyAnimalReceptor Protein-Tyrosine KinasesALK inhibitorIndazoleMechanism of actionALKTrk receptorbiology.proteinCancer researchNeoplasmALK; colorectal cancer; Entrectinib; non-small cell lung cancer; NTRK1; NTRK2; NTRK3; precision medicine; ROS1; salivary gland cancer; TrkA; TrkB; TrkC; Animals; Antineoplastic Agents; Benzamides; Humans; Indazoles; Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptor trkA; Receptor trkB; Receptor trkC; Pharmacology; Pharmacology (medical)Expert Opinion on Investigational Drugs
researchProduct

PO-350 MiRNAs and their relation to biological pathways in left- and right-sided colorectal cancer

2018

Introduction MicroRNAs (miRNAs) are involved in the regulation of gene expression in colorectal cancer (CRC), which has specific biological pathways that are predominant in either left- or right-sided CRC. However, it is unclear how miRNAs are associated with biological pathways in these two forms of CRC. Our hypothesis is that a comprehensive understanding of the fundamental biological signalling pathways in the two sides of CRC may aid in developing a decisive step towards precision medicine. We aim to clarify specific biological pathway differences of differentially expressed miRNAs between left- and right-sided CRC. Material and methods We extracted total RNA from 24 of left- and right-…

Regulation of gene expressionCancer ResearchSmall RNAColorectal cancerWnt signaling pathwayComputational biologyBiologyPrecision medicinemedicine.diseasedigestive system diseasesBiological pathwayOncologymicroRNAmedicinePI3K/AKT/mTOR pathwayESMO Open
researchProduct